News / Blog
New Year Holidays 2024 / 2025
Catalog
Propecia tablets 1 mg for male androgenetic alopecia
Product Code :
Availability : 12
USD 159.00
General information on Japanese tablets Propecia 1 mg for alopecia
Package details: 28 tablets
Manufacturer: MSD K.K., Japan
Active ingredient: finasteride 1 mg
Medical effect: Propecia tablets are effective for treatment of the following diseases and conditions:
- male androgenetic alopecia (male pattern baldness, male hair loss),
- benign prostatic hyperplasia (enlarged prostate),
- excessive hair growth in women,
- hormone therapy for transgender women.
Contraindications and precautions:
Do not use in children, pregnant or breastfeeding women. Do not use in patients planning to undergo a prostate cancer screening.
Dosage and administration of Propecia tablets 1 mg for male androgenetic alopecia from Japan
For male pattern baldness: take 0.2 mg of active ingredient at a time 1 time a day. Please not that 1 tablet contains 1 mg of active ingredient. The consulting doctor may adjust the dosage due to the age and symptoms. But the maximum dosage of 1 mg of active ingredient a day should not be exceeded.
For benign prostatic hyperplasia: take 5 mg of active ingredient 1 time a day. The consulting doctor may adjust the dosage due to the age and symptoms.
About general effects of Propecia tablets 1 mg for male androgenetic alopecia from Japan
Japanese tablets Propecia tablets 1 mg for male androgenetic alopecia are effective for delaying the progress of male-pattern baldness in patients of all ages. Male hair loss is often caused by the miniaturization of the hair follicle due to the excess of dihydrotestosterone. Propecia tablets contain finasteride, a substance that suppresses the production of dihydrotestosterone. Studies show that 6-month treatment with finasteride does not only slow the hair loss, but also reverse it up to the 30% (S. Varothai, W. F. Bergfeld. Androgenetic alopecia: an evidence-based treatment update. American Journal of Clinical Dermatology. July 2014, 15 (3): 217–230).